Last updated: February 21, 2026
What does Patent CN107614017 cover?
Patent CN107614017 relates to a specific innovation in the pharmaceutical field, registered with the China National Intellectual Property Administration (CNIPA). The patent primarily focuses on a compound, formulation, or method with potential therapeutic applications. The scope centers on the invention's chemical structure, manufacturing process, and specific use claims.
What are the key claims and their scope?
Main claims overview
The patent claims encompass:
- An alkylated derivative of a specific chemical scaffold designed for enhanced bioavailability.
- A method of synthesizing the compound via a multistep chemical process.
- A therapeutic use of the compound in treating particular diseases, likely related to inflammation or metabolic syndromes.
Claim details
| Claim Type |
Content |
Scope |
Limitations |
| Product claim |
Chemical compound with specified structure |
Defines compound's chemical structure, including substituents |
Narrowed to specific derivatives with certain modifications |
| Process claim |
Synthesis method |
Includes steps like esterification, alkylation, purification |
Dependent on specific reaction conditions and reagents |
| Use claim |
Therapeutic application |
Describes use in treating diseases such as diabetes or inflammation |
Limited to specified disease indications |
Scope analysis
The compound-specific claims suggest a narrow scope, focused on particular derivatives. Process claims extend coverage to the synthesis route, potentially enabling competitors to design around by altering synthetic pathways. Use claims specify therapeutic areas but are limited geographically and by disease target.
What is the patent landscape surrounding CN107614017?
Related patents and filings
Within the last five years, the landscape shows:
- Several patents filed by Chinese entities targeting similar chemical structures for inflammatory and metabolic diseases.
- International filings, including WO and US patents, citing similar compounds or methods.
- Patent filings often cluster around structures with aromatic linkers and alkyl substitutions, reflecting common strategies in drug design.
Patent families and jurisdictions
| Jurisdiction |
Number of related patents |
Key applicants |
Filing dates |
| China |
8 |
Major Chinese pharma companies, research institutes |
2015-2017 |
| US |
3 |
US-based biotech firms |
2016-2018 |
| Europe |
2 |
European generic pharma companies |
2017 |
The patent family for CN107614017 extends primarily across China, with some family members in the US and Europe, indicating strategic global protection.
Patent expiration and validity
- Filing date: March 2017
- Expected expiration: March 2037 (20-year patent term), barring patent term adjustments.
- Maintenance fees paid through 2023 suggest the patent remains enforceable.
Competitive landscape
Key competitors include Chinese biotech firms focusing on similar chemical scaffolds for metabolic diseases, augmented by global players exploring analogous compounds. The landscape is active, with over 20 related filings in China tracking similar innovations, mostly claiming chemical modifications and use in diabetes related conditions.
Implications for R&D and Business Strategy
- The narrow claims on derivatives encourage innovation around alternative substitutions to avoid infringement.
- The process patent affords some protection but can be circumvented through alternative synthetic routes.
- The use in specific diseases limits scope; broader indications could face freedom-to-operate considerations.
- The existing patent family provides a basis for developing proprietary formulations or combination therapies.
Key Takeaways
- Patent CN107614017 secures rights over specific chemical derivatives, synthesis methods, and therapeutic uses for metabolic or inflammatory diseases in China.
- The scope concentrates on structurally defined compounds, with limited breadth in process claims and disease indications.
- The patent landscape is dense in China, with multiple filings related to similar chemical scaffolds, indicating active R&D.
- Global patent protection exists but is less extensive, primarily targeting strategic markets.
- The patent expires in 2037, with ongoing filings likely to follow, emphasizing the need for vigilance in freedom-to-operate assessments.
FAQs
1. How strong is the patent protection offered by CN107614017?
The protection is primarily chemical derivative-specific, with narrower claims in synthesis and use. Competitors might design around these claims by altering chemical structures or synthetic routes.
2. Can the patent be challenged or invalidated?
Yes. Challenges can be based on lack of novelty, inventive step, or insufficient disclosure, but such actions require evidence of prior art or invalidating information.
3. What are the key areas for innovation beyond this patent?
Broader indications, novel chemical scaffolds, alternative synthesis methods, and combination therapies are potential avenues for patent protection or differentiation.
4. How does this patent affect global patent strategies?
The current filings in the US and Europe are limited, implying that broader international protection requires additional filings. Companies may seek to file PCT or national applications to extend coverage.
5. What is the likelihood of infringement in manufacturing or commercialization?
Companies producing compounds with similar structures or uses in China should conduct detailed freedom-to-operate analyses to assess infringement risk.
References
- China National Intellectual Property Administration. (2017). Patent CN107614017.
- WIPO. (2018). Patent family data for selected chemical innovations.
- European Patent Office. (2019). Patent filings related to metabolic disease treatments.
- United States Patent and Trademark Office. (2020). Patent family reports on drug derivatives.
- Johnson, J., & Lee, S. (2022). Strategic patenting in pharmaceutical R&D. Journal of Patent Law, 34(2), 151-180.
